When medication recalls, withdrawals and safety alerts happen, Cigna Pharmacy quickly communicates the latest details. We assess the situation, identify any impacts and determine necessary next steps.
When recall scenarios arise, we take action to:
Notable recent recalls
|Product||Impact dates||What's happening||Why|
|Glucagon emergency kit for low blood sugar||9/25/21||Eli Lilly and Company announced a voluntary, nationwide recall of lot D239382D, expiration April 2022, of Glucagon emergency kit for low blood sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the consumer/user level.||Vials containing the active ingredient, which should be in powder form, have a liquid formulation instead. As a result, the product may not be potent enough to treat an episode of low blood sugar.|
|Chantix||9/16/21||Pfizer, Inc. expanded its voluntary nationwide recall of Chantix to include all lot numbers. This follows previous recalls in August and July, 2021 affecting only certain lots of the drug. The latest recall has an additional Home Delivery impact for Cigna commercial.||Affected product may contain levels of an impurity, called N-nitroso-varenicline, that are above the U.S. Food and Drug Administration's acceptable intake limit for patients. N-nitroso-varenicline may be associated with a potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication. To date, Pfizer has not received any reports of adverse events related to this recall.|
|Losartan as well as
|9/13/21||Jubilant Cadista Pharmaceuticals announced a market withdrawal of all unexpired lots of Losartan, as well as Losartan/Hydrochlorothiazide, distributed under the Cadista label.||The market withdrawal is due to the presence of a potentially harmful chemical in the tablets.|
|Firvanq, 50mg/mL kit||9/8/21||Voluntary, nationwide recall of certain lots of Firvanq, 50mg/mL Kit.||This recall is due to the wrong diluent being in the box.|
|Lidocaine topical solution||8/27/21||Voluntary, nationwide recall of one lot of Lidocaine Topical Solution.||The solution could be stronger than is indicated on the label.|
|Atovaquone||8/6/21||Recall of certain lots of Atovaquone.||Affected lots may have frozen during shipment and might not be as effective as they should be.|
|saline syringes||8/4/21||Recall of certain lots of saline syringes manufactured by Cardinal Health.||The plungers may not work correctly, which may allow air to get into the syringes.|
Visit the U.S. Food and Drug Administration (FDA)’s website to learn more about the latest recalls, withdrawals and safety alerts.
Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, review your plan documents or contact a Cigna representative.
All Cigna products and service are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Evernorth Care Solutions, Inc., Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., Evernorth, Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.
© 2021 Cigna. All rights reserved